Advertisement

Topics

Search Results for "En Vivo EVP6124 Alzheimer"

12:16 EST 24th February 2017 | BioPortfolio

Matching Channels

Cytoplasmic Protein Tau

One of the main pillars of current drug discovery and development activities in the pharmaceutical industry for Alzheimer's disease is prevention of the accumulation of misfolded proteins, i.e. ...

Histone Deacetylase HDAC Inhibitors

Histone deacetylase (HDAC) inhibitors are emerging as a new class of potential anticancer agents for the treatment of solid and hematological malignancies. HDAC inhibition causes acetylated nuclear ...

Nerve growth factor NGF

Nerve growth factor (NGF) is the prototypical member of the family of neurotrophin growth factors that are involved in the growth and survival of nervous tissue. NGF and its receptors, the tyrosine-...

Interleukin 1 IL 1 Receptor IL 1R

Interleukin-1 (IL-1) beta is a proinflammatory cytokine driving joint inflammation as well as systemic signs of inflammation, such as fever and acute phase protein production. Current therapy targetin...

Selective monoamine oxidase type B MAOB inhibitors

The clinical benefit of monoamine oxidase type B (MAO-B) inhibitors is thought to arise from an ability of these medications to enhance the level of dopamine by decreasing the catabolism. Additional...

Matching News

The effects of different familial Alzheimer’s disease mutations on APP processing in vivo

Disturbed amyloid precursor protein (APP) processing is considered to be central to the pathogenesis of Alzheimer’s disease (AD). The autosomal dominant form of the disease, familial AD (FAD), may s...

Study using Cubresa SPECT scanner finds potential non-invasive diagnosis for Alzheimer’s

Cubresa’s SPECT scanner was used to determine if a novel molecular label, TRV6001, in development for in vivo imaging of the BChE enzyme present in the brains of Alzheimer’s Disease patients follo...

JAD's Alzheimer Funding Analyzer now includes Alzheimer's Association grants

(IOS Press) The Journal of Alzheimer's Disease (JAD) is pleased to announce that its Alzheimer's Funding Analyzer (AFA) now includes all Alzheimer's Association (AA) grants in addition to grants from ...

Major step towards Alzheimer’s blood test

(Nanowerk News) A research team, led by Cardiff University, has made a significant step towards the development of a simple blood test to predict the onset of Alzheimer’s disease (Journal of Alzheim...

Wandering Poses Unique Risks for Persons Living with Alzheimer's and Dementia

Toledo, Ohio (PRWEB) December 27, 2016 Wandering is a challenging behavior of those suffering with Alzheimer's disease and relat...

Alzheimer’s Research: Where We’ve Failed and What’s To Come

Alzheimer’s disease is a rapidly growing public health crisis. Today an estimated 5.4 million Americans live with the disease and, barring the development of medical breakthroughs to prevent, stop o...

How Much Hope Is There For Alzheimer’s Drugs?

Last night, Alzheimer’s researchers held a celebration over their field’s latest failure. A study of Eli Lilly’s experimental Alzheimer’s drug, solanezumab, failed to show a st...

Just How Worthless Are the Standard Alzheimer’s Models?

As mentioned yesterday, Alzheimer’s therapies have, for the most part, been a cliff over which people push bales of money. There are plenty of good reasons for this: we don’t really know w...

Matching PubMed Articles

In vivo Patterns of Tau Pathology, Amyloid-β Burden, and Neuronal Dysfunction in Clinical Variants of Alzheimer's Disease.

The clinical heterogeneity of Alzheimer's disease is not reflected in the rather diffuse cortical deposition of amyloid-β. We assessed the relationship between clinical symptoms, in vivo tau patholog...

Quantitative MRI to understand Alzheimer's disease pathophysiology.

The role of white matter damage in the progression of Alzheimer's disease and the associated cognitive symptoms is becoming increasingly clearer. This is partly because of the advent of diffusion tens...

In vivo cortical spreading pattern of tau and amyloid in the Alzheimer's disease spectrum.

To determine the in vivo cortical spreading pattern of tau and amyloid and to establish positron emission tomography (PET) image-based tau staging in Alzheimer's disease (AD) spectrum.

The application of lipidomics to biomarker research and pathomechanisms in Alzheimer's disease.

Alzheimer's disease is the most common cause of dementia. There are still no disease modifying treatments that can cure or slow disease progression. Recently, Alzheimer's disease researchers have atte...

Kallikrein-8 inhibition attenuates Alzheimer's pathology in mice.

Memory loss and increased anxiety are clinical hallmarks of Alzheimer's disease (AD). Kallikrein-8 is a protease implicated in memory acquisition and anxiety, and its mRNA is known to be up-regulated ...

Search Whole site using Google

Loading
Quick Search
Advertisement
 
Advertisement Advertisement